register

News & Trends - Pharmaceuticals

Fresenius Kabi gains TGA approval for new biosimilar

Health Industry Hub | June 29, 2020 |

Pharma News: Fresenius Kabi secured TGA registration of Idacio, a biosimilar medicine to AbbVie’s Humira (adalimumab).

With global sales of US$20 billion in 2018, AbbVie’s Humira has been a target for a number of biosimilars.

The drug is an antibody treatment for a range of inflammatory conditions, including various forms of arthritis, inflammatory bowel disease and psoriasis.

Fresenius Kabi’s Idacio (adalimumab rch) is approved for:

  • Rheumatoid arthritis as monotherapy or in combination with methotrexate
  • Juvenile idiopathic arthritis – in combination with methotrexate is indicated for reducing the signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis
  • Psoriatic arthritis – moderate to severe disease
  • Ankylosing spondylitis
  • Crohn’s disease in adults and children (≥ 6 years)
  • Ulcerative colitis – moderate to severe disease
  • Psoriasis in adults and children – active moderate to severe hidradenitis suppuratives (acne inversa)
  • Uveitis – non-infectious intermediate, posterior and pan-uveitis

Other adalimumab biosimilars registered in Australia include Amgen’s Amgevita since 2017, Samsung Bioepis’ Hadlima since 2018 and Sandoz’s Hyrimoz since 2019.


Medical and Science

Government fails diabetes patients with no implementation or funding plan

Government fails diabetes patients with no implementation or funding plan

Health Industry Hub | November 5, 2024 |

Medical & Science: Ahead of World Diabetes Day on 14 November, A/Professor Sof Andrikopoulos, CEO of the Australian Diabetes Society […]

More


News & Trends - Pharmaceuticals

Government under fire as Senator Ruston slams decision to defer access to new medicines

Government under fire as Senator Ruston slams decision to defer access to new medicines

Health Industry Hub | November 5, 2024 |

Pharma News: Revelations that as many as 44 new medicines are facing months-long delays under the Albanese Government have sparked […]

More


News & Trends - Pharmaceuticals

Patients call for greater transparency of Australia's most common osteoporosis therapy

Patients call for greater transparency of Australia’s most common osteoporosis therapy

Health Industry Hub | November 5, 2024 |

Pharma News: Consumers should be fully informed about the potential side effects of Australia’s most common osteoporosis treatment, according to […]

More


Medical and Science

Digital solutions: Bridging pharma gaps to deliver real impact for patients and clinicians

Digital solutions: Bridging pharma gaps to deliver real impact for patients and clinicians

Health Industry Hub | November 4, 2024 |

Medical & Science: In today’s era of rapid technological advancements, the integration of digital solutions in healthcare offers both transformative […]

More


This content is copyright protected. Please subscribe to gain access.